The FDA has approved tralokinumab (Adbry) for the treatment of moderate to severe atopic dermatitis (AD) in adults whose disease is not well controlled with topical prescription therapies or when those therapies are not advisable. Administered SC, tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds to interleukin-13, a key driver of underlying inflammation in AD. The drug, which has been developed by LEO Pharma, comes as a single-dose (150 mg) prefilled syringe with needle guard. Between 25% and 33% of patients treated with tralokinumab 300 mg every other week achieved an improvement of 75% or more in the Eczema Area and Severity Index score (EASI-75) versus 13% and 10% with placebo. It can be used with or without topical corticosteroids. Upper respiratory tract infections (23.8%), and conjunctivitis (13.6%) were the most reported side effects (Jan, 2022).
ليست هناك تعليقات:
إرسال تعليق